COAG
COAG
US4234941031
Hemab Therapeutics Holdings, In
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
70.119.000 50.383.000
39.2%
Operating Income -70.119.000 -50.383.000
39.2%
Pretax Income -64.140.000 -48.522.000
32.2%
Net Income Common Stockholders -63.913.000 -48.707.000
31.2%
-- --
--
-- --
--
ende